Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414588 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL2314633 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL16414974 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL16414735 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL15352379 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL7596180 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL1264259 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL16414507 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL16415200 | 1.00 | CA2 (0.53) | CA2SPHK2SPHK1CYP4A11CYP4F2 | |
| SCHEMBL2307575 | 0.98 | CA2 (0.52) | CA2SPHK2SPHK1CYP4A11CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-9579406-B2 | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof | CELLECTAR BIOSCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579406-B2 | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof | CELLECTAR BIOSCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9550002-B2 | Phospholipid analogs as diapeutic agents and methods thereof | CELLECTAR BIOSCIENCES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550002-B2 | Phospholipid analogs as diapeutic agents and methods thereof | CELLECTAR BIOSCIENCES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150093330-A1 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF | CELLECTAR, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150093330-A1 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF | CELLECTAR, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150030538-A1 | PHOSPHOLIPID ETHER ANALOGS AS AGENTS FOR DETECTING AND LOCATING CANCER, AND METHODS THEREOF | CELLECTAR, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | CELL ACQUISITION CORP. | 2008-12-18 | — | — | US | disclosed |
| WO-2008150439-A1 | COMPOSITIONS OF PHOSPHOLIPID ETHER BORONIC ACIDS AND ESTERS AND METHODS FOR THEIR SYNTHESIS AND USE | CELLECTAR, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20070098633-A2 | administering radiolabeled 18-(4-iodophenyl)-octadecylphosphocholine, using computed tomography/positron emission tomography or magnetic resonance imaging to produce visualization of three-dimensional morphology of selected region suspected, giving both anatomical and functional information | CELLECTAR, LLC (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070098633-A2 | administering radiolabeled 18-(4-iodophenyl)-octadecylphosphocholine, using computed tomography/positron emission tomography or magnetic resonance imaging to produce visualization of three-dimensional morphology of selected region suspected, giving both anatomical and functional information | CELLECTAR, LLC (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1773408-A2 | VIRTUAL COLONOSCOPY WITH RADIOLABELED PHOSPHOLIPID ETHER ANALOGS | CELLECTAR, LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070020178-A1 | For detecting and locating recurrence of cancer, radiation and drug resistance, and/or metastasis | CELLECTAR, LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020178-A1 | For detecting and locating recurrence of cancer, radiation and drug resistance, and/or metastasis | CELLECTAR, LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006014589-A2 | VIRTUAL COLONOSCOPY WITH RADIOLABELED PHOSPHOLIPID ETHER ANALOGS | CELLECTAR, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060013767-A1 | Virtual colonoscopy with radiolabeled phospholipid ether analogs | CELLECTAR, LLC (US) | 2006-01-19 | — | — | US | disclosed |
| US-20050196339-A1 | For detecting and locating recurrence of cancer, radiation and drug resistance, and/or metastasis | CELLECTAR, LLC (US) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030538-A1 | PHOSPHOLIPID ETHER ANALOGS AS AGENTS FOR DETECTING AND LOCATING CANCER, AND METHODS THEREOF | PHOSPHO1, LPAR3, PNLIP | CA2 2351/4885SPHK2 142/4885SPHK1 177/4885 |
| US-20070020178-A1 | For detecting and locating recurrence of cancer, radiation and drug resistance, and/or metastasis | RB1, LRAT, LPAR3 | CA2 1976/4885SPHK2 188/4885SPHK1 257/4885 |
| US-20150093330-A1 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF | PHOSPHO1, SGMS1, CDIPT | CA2 3617/4885SPHK2 366/4885SPHK1 329/4885 |
| US-20070098633-A2 | administering radiolabeled 18-(4-iodophenyl)-octadecylphosphocholine, using computed tomography/positron emission tomography or magnetic resonance imaging to produce visualization of three-dimensional morphology of selected region suspected, giving both anatomical and functional information | PHOSPHO1, APC, LPCAT3 | CA2 2551/4885SPHK2 242/4885SPHK1 244/4885 |
| US-20050196339-A1 | For detecting and locating recurrence of cancer, radiation and drug resistance, and/or metastasis | LPCAT3, LPAR3, LPAR4 | CA2 3560/4885SPHK2 126/4885SPHK1 128/4885 |
| US-20060013767-A1 | Virtual colonoscopy with radiolabeled phospholipid ether analogs | PHOSPHO1, APC, NAPEPLD | CA2 3839/4885SPHK2 534/4885SPHK1 609/4885 |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | CA2 1106/4885SPHK2 3055/4885SPHK1 2853/4885 |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | PHOSPHO1, PLEC, PLA2G2C | CA2 2498/4885SPHK2 150/4885SPHK1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.